📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Gilead earnings beat Street estimates, writedown taken on cancer drug

Published 04/28/2022, 04:27 PM
Updated 04/28/2022, 06:26 PM
© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (CO
GILD
-
IMMU
-

By Deena Beasley

(Reuters) - Gilead Sciences Inc (NASDAQ:GILD) on Thursday said its first-quarter revenue rose 3%, helped by sales of HIV drug Biktarvy and COVID antiviral Veklury, but the company reported a net loss as it wrote down the value of its 2020 acquisition of Immunomedics (NASDAQ:IMMU) following recent trial results for cancer drug Trodelvy.

The biotech company said adjusted earnings rose 4% from a year ago to $2.12 per share, topping the average analyst estimate of $1.81, as compiled by Refinitiv.

Revenue for the quarter rose to $6.6 billion from $6.4 billion, ahead of Wall Street estimates of $6.27 billion.

Net income, however, fell to $12 million from $1.72 billion as Gilead took a $2.7 billion research and development impairment charge related to the Immunomedics deal.

Gilead Chief Financial Officer Andrew Dickinson said on a conference call that the company had reassessed the value of those assets at $12 billion - down from its previous view of $14.7 billion.

The company in March said a large Trodelvy trial achieved its goal of delaying tumor growth in women with the most common form of breast cancer, but it has not disclosed specific data from the study.

Dickinson said the accounting change reflects the likelihood of a delayed launch for the drug for that use, as well as the possibility of reduced market share in other indications.

"We continue to see Gilead at a crossroads," BMO Capital Markets analyst Evan Seigerman said in a research note, adding that he was waiting for more data on the company's cancer drugs in development.

First-quarter sales of Trodelvy, which is approved for treating a rare type of breast cancer and bladder cancer, doubled from a year earlier to $146 million.

Gilead's HIV drug sales rose 2% to $3.7 billion, slightly ahead of Wall Street estimates.

Sales of the COVID-19 treatment remdesivir, which is sold under the brand name Veklury, rose 5% to $1.5 billion, exceeding analysts' estimates of $1.15 billion.

© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake

For full-year 2022, the California-based company said it still expects adjusted earnings per share of $6.20 to $6.70 on product sales of $23.8 billion to $24.3 billion.

Gilead shares were down about half a percentage point at $61.71 in after hours trading.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.